Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes

Ebenezer David, Jonathan L. Kaufman, Christopher R. Flowers, Katherine Schafer-Hales, Claire Torre, Jing Chen, Adam I. Marcus, Shi-Yong Sun, Lawrence H. Boise, Sagar Lonial

Blood (2010) 116 (24): 5285–5288.

https://doi.org/10.1182/blood-2010-03-272393

Published: 2010

Includes: Supplemental data

Journal Articles

Patulin Acts Synergistically with Doxorubicin and Bortezomib in Cytotoxicity against Hematological Malignancies

Alex Hessel, Malefa Tselanyane, PhD, Fengrong Wang, MD, PhD, Ebenezer David, PhD, Sagar Lonial, MD, Edmund K. Waller, MD, PhD

Blood (2008) 112 (11): 2664.

https://doi.org/10.1182/blood.V112.11.2664.2664

Published: 2008

Journal Articles

SF1126, a Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequence Specific Synergy When Combined with Bortezomib in Multiple Myeloma Cells

Ebenezer David, PhD, Xiaodong Peng, PhD, Benjamin G Barwick, Jonathan L Kaufman, MD, Joseph R Garlich, PhD, Sagar Lonial, MD

Blood (2008) 112 (11): 5167.

https://doi.org/10.1182/blood.V112.11.5167.5167

Published: 2008

Journal Articles

Imipramine Blue, a Tricyclic Compound and An Inhibitor of NADPH Oxidase Induces G2/M Cell Cycle Arrest Followed by Apoptosis in Multiple Myeloma Cells and in Leukemia Cells

Ebenezer David, PhD, Jonathan L Kaufman, MD, Jack Arbiser, MD, Sagar Lonial, MD

Blood (2008) 112 (11): 5170.

https://doi.org/10.1182/blood.V112.11.5170.5170

Published: 2008

Journal Articles

Combination of Bortezomib with Tipifarnib (R115777) Induces Synergistic Myeloma Cell Apoptosis Via Down-Regulation of HDAC6 and Inhibition of Aggresome Formation.

Ebenezer David, PhD, Katherine Schafer-Hales, Adam I. Marcus, PhD, Jonathan L. Kaufman, MD, Sagar Lonial, MD

Blood (2007) 110 (11): 1520.

https://doi.org/10.1182/blood.V110.11.1520.1520

Published: 2007

Journal Articles

A Novel Pan-PI3K/Akt Inhibitor, SF1126, Inhibits In Vitro Growth of Multiple Myeloma Cells.

Jeannine Silberman, MD, Kimberly Dalbey, BS, Claire Torre, Ebenezer David, PhD, Leif Bergsagel, MD, Donald Durden, MD, PhD, Joseph Garlich, PhD, Ulrich Schwertschlag, MD, PhD, Sagar Lonial, MD

Blood (2007) 110 (11): 4806.

https://doi.org/10.1182/blood.V110.11.4806.4806

Published: 2007

Journal Articles

Perifosine Induces DR4/DR5 Expression Leading to Apoptosis That Can Be Enhanced with Exogenous TRAIL, and Blocked with Strategies Directed at DR4/DR5 Inhibition.

Ebenezer David, PhD, Rajni Sinha, MD, Jonathan L. Kaufman, MD, Sagar Lonial, MD

Blood (2006) 108 (11): 3446.

https://doi.org/10.1182/blood.V108.11.3446.3446

Published: 2006

Journal Articles

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT

Ebenezer David, Shi-Yong Sun, Edmund K. Waller, Jing Chen, Fadlo R. Khuri, Sagar Lonial

Blood (2005) 106 (13): 4322–4329.

https://doi.org/10.1182/blood-2005-06-2584

Published: 2005

Journal Articles

Combination of Akt/PKB Inhibition (Perifosine) and Farnesyl Transferase Inhibition (Tipifarnib) Results in Increased Cell Death in Myeloma Cells Lines.

Rajni Sinha, MD, Ebenezer David, PhD, Emily Zeilter, Claire Torre, Jonathan L. Kaufman, MD, Sagar Lonial, MD

Blood (2005) 106 (11): 1568.

https://doi.org/10.1182/blood.V106.11.1568.1568

Published: 2005

Journal Articles

Combination of Farnesyl Transferase Inhibitor (Tipifarnib) with Perifosine Induces Apoptosis through phos-PDK1 in Human Lymphoma and Leukemia Cell Lines.

Ebenezer David, PhD, Rajni Sinha, MD, Claire Torre, Jonathan L. Kaufman, MD, Sagar Lonial, MD

Blood (2005) 106 (11): 1488.

https://doi.org/10.1182/blood.V106.11.1488.1488

Published: 2005

Journal Articles

Combination of Farnesyl Transferase Inhibition (Lonafarnib) and Proteasome Inhibition (Bortezomib) Results in Rapid Caspase Activation and down Regulation of p-AKT in Myeloma cell Lines and Primary Myeloma Cells.

Ebenezer David, PhD, Shi-Yong Sun, PhD, Fadlo R. Khuri, MD, Sagar Lonial, MD

Blood (2004) 104 (11): 2471.

https://doi.org/10.1182/blood.V104.11.2471.2471

Published: 2004

Journal Articles

Donor Dendritic Cells Regulate Immune Reconstitution after Allogeneic Bone Marrow Transplantation.

Jian-Ming Li, Ph.D., Wayne Harris, B.S., Ebenezer David, Ph.D., Sagar Lonial, M.D., Ned Waller, M.D, Ph.D

Blood (2004) 104 (11): 3073.

https://doi.org/10.1182/blood.V104.11.3073.3073

Published: 2004

NARROW

Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes

Patulin Acts Synergistically with Doxorubicin and Bortezomib in Cytotoxicity against Hematological Malignancies

SF1126, a Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequence Specific Synergy When Combined with Bortezomib in Multiple Myeloma Cells

Imipramine Blue, a Tricyclic Compound and An Inhibitor of NADPH Oxidase Induces G2/M Cell Cycle Arrest Followed by Apoptosis in Multiple Myeloma Cells and in Leukemia Cells

Combination of Bortezomib with Tipifarnib (R115777) Induces Synergistic Myeloma Cell Apoptosis Via Down-Regulation of HDAC6 and Inhibition of Aggresome Formation.

A Novel Pan-PI3K/Akt Inhibitor, SF1126, Inhibits In Vitro Growth of Multiple Myeloma Cells.

Perifosine Induces DR4/DR5 Expression Leading to Apoptosis That Can Be Enhanced with Exogenous TRAIL, and Blocked with Strategies Directed at DR4/DR5 Inhibition.

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT

Combination of Akt/PKB Inhibition (Perifosine) and Farnesyl Transferase Inhibition (Tipifarnib) Results in Increased Cell Death in Myeloma Cells Lines.

Combination of Farnesyl Transferase Inhibitor (Tipifarnib) with Perifosine Induces Apoptosis through phos-PDK1 in Human Lymphoma and Leukemia Cell Lines.

Combination of Farnesyl Transferase Inhibition (Lonafarnib) and Proteasome Inhibition (Bortezomib) Results in Rapid Caspase Activation and down Regulation of p-AKT in Myeloma cell Lines and Primary Myeloma Cells.

Donor Dendritic Cells Regulate Immune Reconstitution after Allogeneic Bone Marrow Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only